Hospital Acquired Infections Therapeutics Market Size & Share 2024 – 2032

Hospital Acquired Infections Therapeutics Market Size

The global hospital acquired infections therapeutics market size was valued at USD 12.6 billion in 2023 and is expected to exhibit growth at a CAGR of 3.2% from 2024 – 2032 period. The hospital-acquired infection (HAIs) market share is being driven by the ever-growing advancement of the occurrence of infections following surgery during hospitalization, the growing focus towards quality patient treatment, and proactive government initiatives aimed at preventing the spread of infections after a patient is admitted to a hospital.

Moreover, the rising trend of admissions as well as the length of inpatient stays and increased use of invasive devices constitutes the major motivators to place a heightened demand for therapeutic interventions targeting urinary tract infections, pneumonia, and bloodstream infections. Furthermore, the rising number of immunocompromised patients is also aiding the growth of HAIs and subsequently the market for HAI therapeutics. Moreover, a greater burden of healthcare-associated infections will also create favorable opportunities for the overall HAI therapeutics market. For instance, according to CDC, 1 in 31 hospital patients in the U.S. on any given day is suffering from some form of healthcare-associated infection.
 

Additionally, a crucial factor influencing the expansion of the HAI therapeutics market is the creation of novel and more efficient antimicrobial therapies, such as antibiotics and antifungals. Many pharmaceutical companies are investing huge amounts of money into combating antibiotic-resistant bacteria by developing new products. The improvement of therapeutics designed for specific pathogens and given for particular types of infection is enhancing market expansion and improving patient outcomes.

Hospital Acquired Infections Therapeutics Market Trends

Several essential trends affect the HAI therapeutics market. Firstly, the adoption of rapid diagnostic methods and molecular diagnostics has greatly improved pathogen detection. This improvement enables more efficient treatment. The second trend is the increased investment in and focus on managing and optimizing the use of antibiotics through stewardship programs that aim to improve outcomes and lessen antibiotic-resistant infections.
 

• New antimicrobial agents, such as bacteriophages and monoclonal antibodies, are being developed for the exceedingly difficult multi-drug resistant organisms. The application of artificial intelligence and machine learning into infection control is gaining traction, as it provides predictive diagnostics for potential outbreaks, treatment protocols, and outbreak anticipation.
   
• While adequate care to combat the spread of HAIs is nonexistent, the focus on infection prevention with the presentation of more sophisticated sterilization techniques and increased protective barriers utilized in healthcare settings to reduce healthcare-associated infections is increasing. On the other hand, the expansion of telemedicine and the remote monitoring approach of dealing with infection is faster and more effective and thus improves the HAI management, especially in outpatient departments.
   

Hospital Acquired Infections Therapeutics Market Analysis

Depending on the type of medication, the market for the treatment of hospital-acquired infections is segmented into antibacterial drugs, antiviral drugs, antifungal drugs, and other medications. The highest revenue of USD 9.2 billion was generated by the sale of antibacterial drugs in 2023.
 

• Antibacterial drugs have grown to be very important in the battle against HAIs and come with a commensurate market share. The increasing spread of antibiotic-resistant bacteria in healthcare facilities has increased the need for stronger antibacterial medicines. These drugs are needed for treating a broad spectrum of bacterial infections, such as those inflicted by Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile as well.
   
• Moreover, efforts focused on developing new antibiotics, especially against these resistant strains, must persist in order to mitigate the impacts of antibiotic resistance. There is significant research and development funding being made available by pharmaceutical companies for the purpose of finding new compounds and improving the strength of current ones with combination therapies. This emphasis on innovation tempered by the urgent need to control resistant infections contributes to the demand for antibacterial drugs within the HAI therapeutics market.
   

Regarding the method of administering medicine, the hospital acquired infections therapeutics market for hospital-acquired infections besides intravenous (IV) includes oral, topical, and inhalation. The intravenous (IV) segment had the largest revenue share of approximately 5.7 billion dollars in the year 2023.
 

• Out of all the methods used in managing hospital acquired infections, intravenous or IV is the most popular technique. The IV method is preferred as administration of drugs using this method happens very quickly and provides immediate delivery of the medication, which is crucial in cases of serious infections.
   
• In the hospitals, patients having a very serious infection that is life-threatening must have high dosages of antibiotics or other therapeutic agents, is administered medications via IV route. Importantly, precise control of the dosage administered as well as continuous IV drops makes this method ideal for the treatment of complicated and severe infections. This is why the IV method has a larger share in the HAI therapeutics market.  
   

Learn more about the key segments shaping this market

Download Free PDF

The hospital acquired infections therapeutics market for medication to treat infections acquired in hospitals is subdivided according to the types of infections such as surgical site infections, bloodstream infections, urinary tract infections, ventilator-induced pneumonia, and others. The segment of surgical site infection was the leading segment in 2023, with an estimated revenue of 5.2 billion US dollars.
 

• Surgical Site Infections (SSIs) are prevalent among HAIs. SSIs account for a large segment and are some of the most critical markers for overall health system effectiveness as they occur in the body tissues affected by the surgery and depend on the health of the patient, the length of the surgery, and the sterility of the operating room.
   
• Moreover, the growing elderly population along with increasing number of surgeries performed increases the incidence of SSIs, which in turn prompts the demand for more sophisticated therapeutic measures such as specialized antibiotics and advanced wound care products to treat and prevent SSIs. In addition, greater focus on patient outcome improvement and mitigating postoperative complications also assists in sharpening focus on SSIs in the HAI therapeutics market.
   

North America hospital acquired infections therapeutics market accounted for USD 4.7 billion market revenue in 2023 and is anticipated to grow at a CAGR of 2.5% between 2024 – 2032 period.
 

• One of the main reasons for the high demand for HAI therapeutics in North America is its sophisticated healthcare infrastructure and the ever-growing incidence of HAIs. Moreover, a large number of hospitals and healthcare facilities increases the chances of acquiring infections while treatment is being provided, which makes infection prevention measures extremely important.
   
• In addition, the presence of leading pharmaceutical companies and their constant R&D efforts allows for the development of advanced therapeutics. The U.S. in particular has a high rate of hospital admissions with simultaneous surgeries and catheterizations, which causes a surge in HAIs. This robust healthcare system is able to implement the latest infection and control practices and therapeutic innovations, thereby creating increased demand for HAI therapeutics.  
   

U.S. hospital acquired infections therapeutics market accounted for USD 4.3 billion market revenue in 2023 and is estimated to record notable growth between 2024 – 2032 period.
 

• The U.S. HAI therapeutics' market share is driven by the large and heterogeneous population in the U.S. The country's healthcare infrastructure is highly advanced, which facilitates the diagnosis and treatment of HAIs.
   
• Moreover, the investment in healthcare pharmaceuticals translates to above and beyond private investment in healthcare research. The loophole in public affairs also escalates the need for more advanced medicines to cater to the rising acceptance of infection antibiotic-resistant strains such as MRSA. The private sector, as well as government, invested in healthcare research, which helps assist the development of more advanced medicines for HAIs. In November 2022, 10 million USD was awarded to Johns Hopkins for the purpose of optimizing their antibiotic treatment on infection-causing bacteria.
   

UK hospital acquired infections therapeutics market is projected to grow remarkably in the coming years.
 

• The need for HAI therapeutics in the UK is shaped by the actions of the NHS and the policies introduced to minimize HAIs. The country has implemented stringent infection prevention regulations within healthcare institutions which include constant assessment and documentation of infection rates.
   
• The UK government backs the research and application of modern therapeutic products with a focus on HAIs management. Furthermore, the growing knowledge of healthcare providers and patients about the dangers of HAI and its repercussions helps the development of the market. The presence of leading pharmaceutical firms as well as ongoing clinical trials for new therapies enhances the market further.
   

Japan holds a dominant position in the Asia Pacific hospital acquired infections therapeutics market.
 

• In Japan, the healthcare system is well integrated and infection control practices are highly sophisticated, which increases the need for medications targeting hospital-acquired infections. The country also has a relatively high elderly demographic which is more prone to infections including HAIs.
   
• Moreover, the Japanese government has taken steps aimed at increasing the use of sophisticated therapeutics as well as improving infection control in medical facilities. Also, Japan's emphasis on innovation and technology in healthcare leads to advanced treatments for HAIs. Additionally, the pharmaceutical sector of the country is proactive in developing novel therapeutics, making significant investment in R&D.
   

Hospital Acquired Infections Therapeutics Market Share

Some major companies including Pfizer, Merck & Co., and GlaxoSmithKline are engaged in the innovation of new antimicrobial agents and other pharmacological treatment of HAIs. New industry initiatives include novel antibiotics for multi-drug resistant organisms, the development of which is anticipated to increase the control of HAIs and consequently expand the business opportunities for the industry.
 

Hospital Acquired Infections Therapeutics Market Companies

Prominent players operating in the hospital acquired infections therapeutics industry include:

• Abbott
• AbbVie
• Allergan Plc
• Eugia Pharma
• Bayer
• DAIICHI SANKYO COMPANY
• F. Hoffmann-La Roche
• Glenmark Pharmaceuticals
• GSK
• Hikma Pharmaceuticals
• Melinta Therapeutics
• Merck & Co.
• Pfizer
• Sanofi
• Viatris
   
• GSK employs public-private partnerships to improve access to antimicrobial therapies in emerging markets. These markets help confront hospital-acquired infections on a global scale.
   
• Merck focuses on acquisitions and partnerships, to increase the product range for infectious diseases.
   
• Pfizer places value on increasing investment in research and development to foster innovation in anti-infective therapy, for range capturing resistant pathogens through advanced antibiotics and vaccines.
   

Hospital Acquired Infections Therapeutics Industry News:

• In October 2023, Spartan Medical Inc. launched a new campaign to raise awareness about surgical site infections (SSIs) and their consequences across the U.S. This strategy aims to educate healthcare professionals and patients about the risks associated with SSIs and the importance of prevention, thereby driving demand for advanced infection control measures and therapeutic solutions. The campaign strengthens Spartan Medical’s position in the infection control market, highlighting its commitment to addressing critical healthcare challenges.
   
• In April 2024, Basilea Pharmaceutica International Ltd. achieved a significant milestone by receiving FDA approval for its new drug, Zevtera, designed to treat bloodstream infections. This approval marks a key strategic move, positioning Basilea as a leader in the HAI therapeutics market. Zevtera’s approval will expand treatment options for severe infections, contributing to improved patient outcomes and reinforcing Basilea's market presence with innovative solutions.
   

The hospital acquired infections therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Antibacterial drugs
• Antiviral drugs
• Antifungal drugs
• Other drug types

Market, By Route of Administration

• Intravenous (IV)
• Oral
• Topical
• Inhalation

Market, By Infection Type

• Surgical site infections
• Bloodstream infections
• Urinary tract infections
• Ventilator-associated pneumonia
• Other hospital infections

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE